4
Changes in Ownership
Aclaris Therapeutics, Inc. Filed Acc 0001415889-25-000623
Chief Financial Officer gave up 38,221 shares (to pay taxes)
- Chief Financial Officer acquired 94,450 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Balthaser Kevin Chief Financial Officer | 2024-12-31 | Option exercise | +73,750 | 98,447 | D | ||
| Balthaser Kevin Chief Financial Officer | 2024-12-31 | Shares withheld for taxes | −30,732 | $2.48 | $76,215 | 67,715 | D |
| Balthaser Kevin Chief Financial Officer | 2025-01-01 | Option exercise | +7,500 | 75,215 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-01-01 | Shares withheld for taxes | −2,430 | $2.48 | $6,026 | 72,785 | D |
| Balthaser Kevin Chief Financial Officer | 2025-01-02 | Option exercise | +13,200 | 85,985 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-01-02 | Shares withheld for taxes | −5,059 | $2.48 | $12,546 | 80,926 | D |
| Derivatives | |||||||
| Balthaser Kevin Chief Financial Officer | 2024-12-31 | Option exercise · Restricted Stock Units | −73,750 | 73,750 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-01-01 | Option exercise · Restricted Stock Units | −7,500 | 15,000 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-01-02 | Grant or award · Restricted Stock Units | +40,000 | 40,000 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-01-02 | Option exercise · Restricted Stock Units | −13,200 | 26,800 | D | ||
Loading xslF345X05/form4-01032025_060106.xml…